Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.


Access options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Figure 1: Ivacaftor.


  1. 1

    O'Sullivan, B. P. & Freedman, S. D. Cystic fibrosis. Lancet 373, 1891–1904 (2009).

    Article  Google Scholar 

  2. 2

    Van Goor, F. et al. Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770. Proc. Natl Acad. Sci. USA 106, 18825–18830 (2009).

    CAS  Article  Google Scholar 

  3. 3

    US Food and Drug Administration. FDA labeling information — Kalydeco. FDA website [online], (2012).

  4. 4

    Ramsey, B. W. et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N. Engl. J. Med. 365, 1663–1672 (2011).

    CAS  Article  Google Scholar 

  5. 5

    Sermet-Gaudelus, I. et al. Ataluren (PTC124) induces cystic fibrosis transmembrane conductance regulator protein expression and activity in children with nonsense mutation cystic fibrosis. Am. J. Respir. Crit. Care Med. 182, 1262–1272 (2010).

    CAS  Article  Google Scholar 

  6. 6

    Clancy, J. P. et al. Results of a Phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation. Thorax 67, 12–18 (2012).

    CAS  Article  Google Scholar 

  7. 7

    Yu, H. et al. Ivacaftor potentiation of multiple CFTR channels with gating mutations. J. Cyst. Fibros. 30 Jan 2012 (doi:10.1016/j.jcf.2011.12.005).

    CAS  Article  Google Scholar 

Download references

Author information



Corresponding authors

Correspondence to Pamela B. Davis, Uma Yasothan or Peter Kirkpatrick.

Ethics declarations

Competing interests

Pamela B. Davis has patents on gene therapy approaches to cystic fibrosis and other diseases that are currently licensed to Copernicus Therapeutics.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Davis, P., Yasothan, U. & Kirkpatrick, P. Ivacaftor. Nat Rev Drug Discov 11, 349–350 (2012).

Download citation

Further reading


Quick links